These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 37431718)
1. The use of a tumor necrosis factor inhibitor-adalimumab-in the management of arthritis in an adolescent with HIV: A case report. Bakry R; Bokhary N; Sendi E; Alshehri M; Sindi L; Alkwai H Int J Rheum Dis; 2024 Jan; 27(1):e14827. PubMed ID: 37431718 [TBL] [Abstract][Full Text] [Related]
2. Successful use of antitumor necrosis factor-alpha biological therapy in managing human immunodeficiency virus-associated arthritis: three case studies from Saudi Arabia. Almoallim H; Jali I; Wali G Joint Bone Spine; 2013 Jul; 80(4):426-8. PubMed ID: 23453475 [TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038 [TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. Weiss PF; Xiao R; Brandon TG; Pagnini I; Wright TB; Beukelman T; Morgan-DeWitt E; Feudtner C J Rheumatol; 2018 Jan; 45(1):107-114. PubMed ID: 28916542 [TBL] [Abstract][Full Text] [Related]
5. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133 [TBL] [Abstract][Full Text] [Related]
6. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study. Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150 [TBL] [Abstract][Full Text] [Related]
7. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698 [TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Joseph GJ; Harrison DJ; Sauer BC Adv Ther; 2016 Aug; 33(8):1347-59. PubMed ID: 27352377 [TBL] [Abstract][Full Text] [Related]
9. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis. Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724 [TBL] [Abstract][Full Text] [Related]
10. Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review. Liang SJ; Zheng QY; Yang YL; Yang Y; Liu CY Rheumatol Int; 2017 Jul; 37(7):1207-1212. PubMed ID: 28255643 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy. Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620 [TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis. Ho Lee Y; Gyu Song G Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982 [TBL] [Abstract][Full Text] [Related]
13. Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients. Yang Y; Wu B; Tian P; Huang L Int J Rheum Dis; 2023 Aug; 26(8):1521-1528. PubMed ID: 37382403 [TBL] [Abstract][Full Text] [Related]
14. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516 [TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept. Gholami A; Azizpoor J; Aflaki E; Rezaee M; Keshavarz K Biomed Res Int; 2021; 2021():4450162. PubMed ID: 34877355 [TBL] [Abstract][Full Text] [Related]
16. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers. Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942 [TBL] [Abstract][Full Text] [Related]
17. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis. Santos-Moreno P; Sánchez G; Gómez D; Bello-Gualtero J; Castro C J Clin Rheumatol; 2016 Mar; 22(2):57-62. PubMed ID: 26886438 [TBL] [Abstract][Full Text] [Related]
18. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. Bodio C; Grossi C; Pregnolato F; Favalli EG; Biggioggero M; Marchesoni A; Murgo A; Filippini M; Migliorini P; Caporali R; Pellerito R; Ciccia F; Sarzi-Puttini P; Perosa F; Paolazzi G; Hollan I; Bendtzen K; Meroni PL; Borghi MO Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206 [TBL] [Abstract][Full Text] [Related]
20. Case report: Safety and efficacy of adalimumab in treating difficult-to-treat rheumatoid arthritis in a human immunodeficiency virus-positive patient, one year follow-up. Chen JW; Deng GS; Zhang WS; Zhang MY; Guan T; Xu Q Front Immunol; 2022; 13():942642. PubMed ID: 35990692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]